TY - JOUR
T1 - Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score
T2 - Prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs
AU - Emanuel, Robyn M.
AU - Dueck, Amylou C.
AU - Geyer, Holly L.
AU - Kiladjian, Jean Jacques
AU - Slot, Stefanie
AU - Zweegman, Sonja
AU - Te Boekhorst, Peter A.W.
AU - Commandeur, Suzan
AU - Schouten, Harry C.
AU - Sackmann, Federico
AU - Fuentes, Ana Kerguelen
AU - Hernández-Maraver, Dolores
AU - Pahl, Heike L.
AU - Griesshammer, Martin
AU - Stegelmann, Frank
AU - Doehner, Konstanze
AU - Lehmann, Thomas
AU - Bonatz, Karin
AU - Reiter, Andreas
AU - Boyer, Francoise
AU - Etienne, Gabriel
AU - Ianotto, Jean Christophe
AU - Ranta, Dana
AU - Roy, Lydia
AU - Cahn, Jean Yves
AU - Harrison, Claire N.
AU - Radia, Deepti
AU - Muxi, Pablo
AU - Maldonado, Norman
AU - Besses, Carlos
AU - Cervantes, Francisco
AU - Johansson, Peter L.
AU - Barbui, Tiziano
AU - Barosi, Giovanni
AU - Vannucchi, Alessandro M.
AU - Passamonti, Francesco
AU - Andreasson, Bjorn
AU - Ferarri, Maria L.
AU - Rambaldi, Alessandro
AU - Samuelsson, Jan
AU - Birgegard, Gunnar
AU - Tefferi, Ayalew
AU - Mesa, Ruben A.
PY - 2012/11/20
Y1 - 2012/11/20
N2 - Purpose: Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and alleviation of this burden represents a paramount treatment objective in the development of MPN-directed therapies. We aimed to assess the utility of an abbreviated symptom score for the most pertinent and representative MPN symptoms for subsequent serial use in assessing response to therapy. Patients and Methods: The Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (MPN-SAF TSS) was calculated as the mean score for 10 items from two previously validated scoring systems. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers. Results: MPN-SAF TSS was calculable for 1,408 of 1,433 patients with MPNs who had a mean score of 21.2 (standard deviation [SD], 16.3). MPN-SAF TSS results significantly differed among MPN disease subtypes (P < .001), with a mean of 18.7 (SD, 15.3), 21.8 (SD, 16.3), and 25.3 (SD, 17.2) for patients with essential thrombocythemia, polycythemia vera, and myelofibrosis, respectively. The MPN-SAF TSS strongly correlated with overall quality of life (QOL; r = 0.59; P < .001) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) functional scales (all P < .001 and absolute r ≥ 0.50 except social functioning r = 0.48). No significant trends were present when comparing therapy subgroups. The MPN-SAF TSS had excellent internal consistency (Cronbach's α = .83). Factor analysis identified a single underlying construct, indicating that the MPN-SAF TSS is an appropriate, unified scoring method. Conclusion: The MPN-SAF TSS is a concise, valid, and accurate assessment of MPN symptom burden with demonstrated clinical utility in the largest prospective MPN symptom study to date. This new prospective scoring method may be used to assess MPN symptom burden in both clinical practice and trial settings.
AB - Purpose: Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and alleviation of this burden represents a paramount treatment objective in the development of MPN-directed therapies. We aimed to assess the utility of an abbreviated symptom score for the most pertinent and representative MPN symptoms for subsequent serial use in assessing response to therapy. Patients and Methods: The Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (MPN-SAF TSS) was calculated as the mean score for 10 items from two previously validated scoring systems. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers. Results: MPN-SAF TSS was calculable for 1,408 of 1,433 patients with MPNs who had a mean score of 21.2 (standard deviation [SD], 16.3). MPN-SAF TSS results significantly differed among MPN disease subtypes (P < .001), with a mean of 18.7 (SD, 15.3), 21.8 (SD, 16.3), and 25.3 (SD, 17.2) for patients with essential thrombocythemia, polycythemia vera, and myelofibrosis, respectively. The MPN-SAF TSS strongly correlated with overall quality of life (QOL; r = 0.59; P < .001) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) functional scales (all P < .001 and absolute r ≥ 0.50 except social functioning r = 0.48). No significant trends were present when comparing therapy subgroups. The MPN-SAF TSS had excellent internal consistency (Cronbach's α = .83). Factor analysis identified a single underlying construct, indicating that the MPN-SAF TSS is an appropriate, unified scoring method. Conclusion: The MPN-SAF TSS is a concise, valid, and accurate assessment of MPN symptom burden with demonstrated clinical utility in the largest prospective MPN symptom study to date. This new prospective scoring method may be used to assess MPN symptom burden in both clinical practice and trial settings.
UR - http://www.scopus.com/inward/record.url?scp=84869381382&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84869381382&partnerID=8YFLogxK
U2 - 10.1200/JCO.2012.42.3863
DO - 10.1200/JCO.2012.42.3863
M3 - Article
C2 - 23071245
AN - SCOPUS:84869381382
SN - 0732-183X
VL - 30
SP - 4098
EP - 4103
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 33
ER -